Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US, UK, Canada Agree On Good Machine Learning Practices

Executive Summary

The principals recommended by the three countries could be the foundation for how their regulatory bodies intend to regulate future AI/ML products.

You may also be interested in...



FDA Publishes 5 PCCP Principles For ML Devices In Collaboration With Canada And UK

Five guiding principles for PCCPs for ML devices exemplify international harmonization efforts from regulators.

FDA’s CDER Is Fostering Use Of Artificial Intelligence In Drug Development

Center for Drug Evaluation and Research plans to issue a request for information this year to engage stakeholders on issues related to AI and machine learning. It received 175 AI/ML submissions in 2022, up from 14 in 2020.

Digital Health Roundup: Digital Therapeutics Push Ahead On Standards, Coverage; FDA’s Software Guidance

In this roundup feature focusing on developments in digital health, we highlight the key news and announcements from October.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT144650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel